Literature DB >> 17032424

Outcome after kidney transplantation in children with thrombotic risk factors.

Birgitta Kranz1, Udo Vester, Silvio Nadalin, Andreas Paul, Christoph E Broelsch, Peter F Hoyer.   

Abstract

BACKGROUND: According to the data from the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS), vascular thrombosis accounts for 11.6% of graft losses in pediatric renal transplantation. In adults, inherited and acquired thrombophilic risk factors, e.g. factor V Leiden mutation, have been associated with early graft loss and increased rejection episodes. Data on the impact of these factors on the outcome of children after renal transplantation are rare. METHODS/PATIENTS: Sixty-six pediatric patients awaiting renal transplantation (mean age 10.1 yr) were screened for inherited and acquired risk factors for hypercoagulable disorders (protein C, S, and antithrombin III deficiency, antiphospholipid antibodies, factor V Leiden, prothrombin, and MTHFR mutation) in order to intensify anticoagulation in those with an increased risk for thrombophilia: intravenous heparin was administered with a partial prothrombin time (PTT) prolongation of 50 s for 14 days and switched to low-molecular-weight heparin for another 8 wk before aspirin was introduced for the first year. Patients without hypercoagulable risk factors were treated with heparin without PTT prolongation for 14 days and switched to aspirin immediately afterwards. The results on graft survival, incidence of acute rejection episodes, and long-term renal graft function were analyzed between recipients with and without hypercoagulable risk factors.
RESULTS: Thrombophilic risk factors were identified in 27.3% of our patients. No thrombosis occurred. One serious bleeding complication led to a second surgical intervention. The rate of acute rejection episodes was not increased in patients with and without thrombotic risk factors after 90 days (16.7 vs. 25%), 1 yr (22.2 vs. 33.3%), and 3 yr (38.9 vs. 41.7%) of follow-up, respectively (p = n.s.). After a mean follow-up of 3 yr the kidney function was comparable in both groups, with 63.1 in recipients with and 69.8 mL/min/1.73 m(2) in recipients without hypercoagulable risk (p = n.s.). At latest follow-up, three graft losses were found not to be attributed to thrombotic risk factors.
INTERPRETATION: Children with thrombophilic risk factors were identified and treated with an intensified anticoagulation regimen after renal transplantation. An increased risk for graft failure, acute rejection episodes, or impaired renal function for pediatric renal transplant recipients with hypercoagulable status was not found.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17032424     DOI: 10.1111/j.1399-3046.2005.00483.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  5 in total

1.  2018 CUA Abstracts.

Authors: 
Journal:  Can Urol Assoc J       Date:  2018-06       Impact factor: 1.862

2.  Renal allograft loss due to renal vascular thrombosis in the US pediatric renal transplantation.

Authors:  Chia-Shi Wang; Larry A Greenbaum; Rachel E Patzer; Rouba Garro; Barry Warshaw; Roshan P George; Pamela D Winterberg; Kavita Patel; Julien Hogan
Journal:  Pediatr Nephrol       Date:  2019-05-26       Impact factor: 3.714

3.  Non-immunologic allograft loss in pediatric kidney transplant recipients.

Authors:  Isa F Ashoor; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2018-02-26       Impact factor: 3.714

Review 4.  Acute graft thrombosis in patients who underwent renal transplant and received anticoagulant or antiplatelet agents. A systematic review and meta-analysis.

Authors:  Rodrigo Guerra; Paulo Roberto Kawano; Marcelo Petean Amaro; Hamilto Akihissa Yamamoto; Fernando Ferreira Gomes Filho; João Luiz Amaro; Regina Paolucci El Dib; Herney Andres Garcia-Perdomo; Leonardo Oliveira Reis
Journal:  Am J Clin Exp Urol       Date:  2022-06-15

5.  Identification of risk factors for vascular thrombosis may reduce early renal graft loss: a review of recent literature.

Authors:  Anna Krarup Keller; Troels Munch Jorgensen; Bente Jespersen
Journal:  J Transplant       Date:  2012-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.